Genetically engineered mouse models (GEMMs) for BC developed previously utilize transgenes for Cre recombinase driven by mammary-specific promoters, to drive loss of Trp53 alone or in combination with loss of Brca1 or Rb1 in mammary tissue [10–13]. The gene discussed is BRCA1; the disease is breast cancer.